论文部分内容阅读
目的:评价乙酰半胱氨酸组泡腾片与噻托溴铵联用治疗慢性阻塞性肺疾病(COPD)患者的临床疗效。方法:选取2014年11月—2015年7月间收治的COPD患者80例,按照分层随机法,将其分成乙酰半胱氨酸组、噻托溴铵组、联用组和对照组患者,每组20例;对照组患者患者均给予常规吸氧及祛痰药治疗;乙酰半胱氨酸组患者在对照组患者基础上给予乙酰半胱氨酸组泡腾片治疗;噻托溴铵组患者在对照组患者基础上给予噻托溴铵治疗;联合组患者在对照组患者基础上给予乙酰半胱氨酸组泡腾片与噻托溴铵治疗,比较4组患者治疗后的临床疗效和肺功能各指标的变化情况。结果:4组患者治疗后3月6 min步行距离(6 MWD)、呼吸困难评分值均优于治疗前(P<0.05);4组患者治疗后3月用力肺活量(FVC)、1 s用力呼气容积(FEV1)和1 s用力呼气容积占用力肺活量(FEV1/FVC)百分比(%)水平值均优于治疗前(P<0.05);联用组患者治疗后FVC和FEV1高于其他各组(P<0.05);而FEV1/FVC百分比(%)与其他各组经比较其差异有统计学意义(P>0.05)。结论:乙酰半胱氨酸组泡腾片与噻托溴铵联用治疗慢性阻塞性肺疾病患者的临床疗效优于其他组的治疗。
OBJECTIVE: To evaluate the clinical efficacy of acetylcysteine combined with tiotropium in the treatment of patients with chronic obstructive pulmonary disease (COPD). Methods: Totally 80 COPD patients who were admitted between November 2014 and July 2015 were divided into three groups according to stratified randomization: acetylcysteine, tiotropium, combination group and control group, Each group of 20 patients; control patients were given conventional oxygen and expectorant medicine treatment; patients with acetylcysteine in the control group were given acetylcysteine group effervescent tablets treatment; tiotropium group The patients were treated with tiotropium on the basis of the control group. The patients in the combination group were treated with acetylcysteine effervescent tablets and tiotropium on the basis of the control group. The clinical efficacy and the clinical efficacy after treatment were compared between the 4 groups. Changes in various indexes of lung function. Results: The scores of walking distance (6MWD) and dyspnea score of the four groups were all better than those before treatment (P <0.05) after 6 months of treatment. The forced vital capacity (FVC) (FEV1) and forced expiratory volume (FEV1 / FVC) at 1 s (%) were better than those before treatment (P <0.05). The FVC and FEV1 in the combined group were higher than those in other groups (P <0.05). However, the percentage of FEV1 / FVC was significantly different from other groups (P> 0.05). Conclusion: Acetylcysteine group effervescent tablets combined with tiotropium in the treatment of patients with chronic obstructive pulmonary disease clinical efficacy is superior to other groups.